
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is a clinical-stage biopharmaceutical company focused on developing products for ADHD and anxiety, with a potential FDA approval for its first product in 2026. They are leveraging their proprietary drug delivery platform technology to develop once-daily tablets for these conditions, and currently have two proprietary stimulant medications in development for ADHD. With a current focus on ADHD and limited market penetration assumptions, there is significant potential for growth and a strong commercial opportunity for Cingulate in the future.
Bears say
Cingulate is facing significant risks to reach their share price target due to financial and regulatory challenges, increased competition, and uncertain investor sentiment. With a focus on ADHD and anxiety treatments, there may also be potential for future product development, but the lack of current profitability and market dependence on their proprietary drug delivery technology could hinder overall success. Additionally, the company's balance sheet and liquidity could limit their ability to weather any unexpected challenges ahead.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares